[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
Continued Growth of the Powder Hemostat Surgical Market in Europe Creates Demand for Starch’s Innovative SuperClot® Technology
Starch Medical reports they received CE Approval earlier this year for SuperClot® and will utilize their existing network of distribution partners along with new strategic partners to bring this innovative new polymer hemostat solution to surgical teams and hospitals throughout Europe. Next week Starch Medical will exhibit and hold distributor meetings at MEDICA the world’s leading trade fair for the medical industry held in Düsseldorf, Germany from November 13-16, 2017.
Giovanni Capello, Chief Executive Officer of Medix said, “The market for economical, safe and effective polysaccharide hemostats is growing rapidly worldwide and especially in Europe. Our exclusive agreement to market Starch Medical’s SuperClot® Hemostat in Italy provides us with the opportunity to better serve our hospitals and their patients. In addition to rapid and effective hemostasis, our surgeons are attracted by the wide variety of surgical applications where SuperClot® can be used.” He added, “We believe that Starch Medical’s hemostat product line including SealFoam®, SealFoam® Sternal and now SuperClot® will become the standard to control the majority of surgical bleeding in the future.”
“Surgeons and hospitals around the world are rapidly adopting the benefits of our hemostatic platform technology to enhance their performance in addressing various bleeding scenarios,” stated Stephen Heniges, President at Starch Medical. “Since our products contain no human or animal components the safety profile is excellent. The ability of SuperClot® to rapidly penetrate blood and form an adhesive gel to help seal the wound will be greatly appreciated by our customers.”
Starch Medical will continue to expand its product portfolio and pursue strategic partners in key markets globally and expects to further penetrate Asia, Europe and The Middle East in the near future.